{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:54:29Z","timestamp":1789786469871,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2018.12.003","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T18:13:16Z","timestamp":1544638396000},"page":"125-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Recent advances in the therapeutic development for Huntington disease"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6973-7479","authenticated-orcid":false,"given":"Tiago A.","family":"Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.003_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib2","series-title":"GeneReviews(R)","article-title":"Huntington disease","author":"Warby","year":"1993"},{"issue":"11","key":"10.1016\/j.parkreldis.2018.12.003_bib3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(18)30294-1","article-title":"Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis","volume":"17","author":"Fusilli","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jns.2008.09.029","article-title":"Late onset Huntington Disease: clinical and genetic characteristics of 34 cases","volume":"276","author":"Lipe","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.12.003_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with huntington disease a randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"Jama-J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.12.003_bib6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.parkreldis.2018.12.003_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","article-title":"Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea","volume":"74","author":"Frank","year":"2017","journal-title":"Jama Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.12.003_bib8","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib9","series-title":"Pharmacodynamic Biomarkers for HTT-lowering Therapies - a White Paper","author":"Macdonald","year":"2015"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib10","author":"Ionis Pharmaceuticals"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib11","series-title":"HTT Rx CS1 Trial Palm Springs","author":"Tabrizi","year":"2016"},{"issue":"5","key":"10.1016\/j.parkreldis.2018.12.003_bib12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","article-title":"Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.12.003_bib13","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.12.003_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JHD-170269","article-title":"Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay","volume":"6","author":"Fodale","year":"2017","journal-title":"J. Huntingt. Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.12.003_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.nbd.2011.12.030","article-title":"Gene therapy for Huntington's disease","volume":"48","author":"Ramaswamy","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fnmol.2014.00050","article-title":"Systemic gene delivery to the central nervous system using Adeno-associated virus","volume":"7","author":"Bourdenx","year":"2014","journal-title":"Front. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.12.003_bib17","article-title":"Metal protein attenuating compounds for the treatment of Alzheimer's dementia","author":"Sampson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.12.003_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","article-title":"Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"14","author":"Investigators HSGRH","year":"2015","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.12.003_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JHD-120029","article-title":"PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6\/2 mouse model of huntington's disease","volume":"1","author":"Cherny","year":"2012","journal-title":"J Huntingt. Dis"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib20","series-title":"FDA End of Phase 2 Status Update","author":"Biotechnology","year":"2015"},{"issue":"23","key":"10.1016\/j.parkreldis.2018.12.003_bib21","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.12.003_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","article-title":"An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease","volume":"79","author":"Sussmuth","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2014-309032.294","article-title":"Safety and tolerability of selisistat for the treatment of huntington's disease: results from a randomised, double-blind, placebo-controlled phase II trial","volume":"85","author":"Reilmann","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2147\/DDDT.S55308","article-title":"Laquinimod in the treatment of multiple sclerosis: a review of the data so far","volume":"10","author":"Thone","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"issue":"11","key":"10.1016\/j.parkreldis.2018.12.003_bib25","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","article-title":"Targets for future clinical trials in Huntington's disease: what's in the pipeline?","volume":"29","author":"Wild","year":"2014","journal-title":"Mov. Disord."},{"issue":"Pt A","key":"10.1016\/j.parkreldis.2018.12.003_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.expneurol.2016.06.008","article-title":"Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons","volume":"283","author":"Ehrnhoefer","year":"2016","journal-title":"Exp. Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2018.12.003_bib27","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/mds.25964","article-title":"HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3","volume":"29","author":"Stout","year":"2014","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2018.12.003_bib28","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.23816","article-title":"Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures","volume":"26","author":"Reilmann","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib29","unstructured":"A. Biotech, [July 31, 2018]. Available from: https:\/\/www.activebiotech.com\/en\/media\/pressreleases\/?id=2208124&date=1533024900."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.12.003_bib31","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pages","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099520","article-title":"Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6\/2 and zQ175 mouse models of Huntington's disease","volume":"9","author":"Menalled","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.003_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.27010","article-title":"A randomized, double-blind, placebo-controlled trial evaluating cysteamine in huntington's disease","volume":"32","author":"Verny","year":"2017","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.12.003_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/JHD-140129","article-title":"Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6\/2 and BACHD mouse models of Huntington's disease","volume":"3","author":"Miller","year":"2014","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.nbd.2012.11.016","article-title":"Phosphodiesterase 10A (PDE10A) localization in the R6\/2 mouse model of Huntington's disease","volume":"52","author":"Leuti","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"14","key":"10.1016\/j.parkreldis.2018.12.003_bib36","first-page":"1843","article-title":"Imaging of phosphodiesterase 10A (PDE10A) enzyme and D2 receptor levels in the living brain of Huntington's disease gene expansion carriers and healthy controls","volume":"29","author":"Fitzer-Attas","year":"2014","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.12.003_bib37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","article-title":"Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging","volume":"86","author":"Russell","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib38","first-page":"S63","article-title":"Examining expression of phosphodiesterase 10A (PDE10A) in Huntington's disease using 18F-MNI-659 PET","volume":"28","author":"Jennings","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib39","first-page":"S539","article-title":"Dopamine D2 receptor and phosphodiesterase 10A loss in Huntingtons disease measured with high-resolution PET and partial volume effect correction","volume":"30","author":"Fitzer-Attas","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib40","series-title":"PDE10A ICM Trial","author":"Delnomdedieu","year":"2016"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib41","unstructured":"E. Wild, J. Carroll, (2017), Available from: https:\/\/en.hdbuzz.net\/229."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.003_bib42","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"J. Pharmacol. Sci."},{"issue":"18","key":"10.1016\/j.parkreldis.2018.12.003_bib43","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington disease","volume":"25","author":"Geva","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib44","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2018.12.003_bib45","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease","volume":"28","author":"Investigators","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.003_bib46","author":"Teva"},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.003_bib47","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00259-016-3324-6","article-title":"Current status of PET imaging in Huntington's disease","volume":"43","author":"Pagano","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.12.003_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from enroll-HD, a global clinical research platform for huntington's disease","volume":"4","author":"Landwehrmeyer","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.parkreldis.2018.12.003_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fnmol.2016.00030","article-title":"CRISPR\/Cas9: implications for modeling and therapy of neurodegenerative diseases","volume":"9","author":"Yang","year":"2016","journal-title":"Front. Mol. Neurosci."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:20:40Z","timestamp":1605615640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018305297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":49,"alternative-id":["S1353802018305297"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.003","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the therapeutic development for Huntington disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}